The researchers at the University of Rey Juan Carlos and the University of Paris PSL have developed a new photosensitivity with nanoparticles of silica and ruthenium. When these types of drugs are activated in cancer cells, they facilitate their elimination, less invasive photodynamic therapy for the patient.
The study has formulated mesoporous nanoparticles of less than 80 nanometers, and with a derived ruthenium. / URJC
The use of metallic drugs, metallic compounds with chemotherapeutic properties in cancer treatments, is of great interest to patients of different types of tumors. According to the calculations, 60% of all cancer patients have been treated with metal compounds, especially platinum, at least once in the development of the disease.
However, metal compounds have therapeutic problems because they have a lot of problems and they are resistant to side effects and tumors. Additionally, in biological media the solubility problems and limitations have been administered as doses administered in certain patients with immune system resulting from the progression of tumors.
The development of new drug nano-formulations used in different antibody therapies, like photodynamics, is one of the lines of research in the COMET-NANO Rey Juan Carlos University. "These therapies, thanks to the discovery of photosensitization, make specific exposure to specific types of light create specific oxygen to act against death-related cancer cells," explains Santiago Gómez-Ruiz, researcher at the COMET-NANO team.
Photosensitizers are used to make photodynamic therapies. When the cancer cells are absorbed and illuminated, the drug is activated and it destroys the cancer cells.
The latest work in this field has formulated silicone mesopores with a size of less than 80 nanometers, and has a radiant derivative of Ruthenium (Ru, low toxicity of metals) with a photodynamic activity under the UV-A light. "Our goal is to study Ruthenium-like nanomaterial systems and similar in the treatment of tumors in a photodynamic," says Gómez-Ruiz.
This work is the result of collaboration with Professor Gilles Gasser (ERC Consolidator) Chimie ParisTech Researchers at the Paris PSL University (France) and Zurich University (Switzerland). Published in the journal Dalton Transactions, A special volume called "Bioinspired Reactivity of Coordination Compounds" should be awaiting publication..
Innovative drugs and future clinical trials
Currently, there is only one form of a ruthenium compound that is currently undergoing clinical palette, the 1414 TLD of the Mc Farland Group (UNC Greensboro, United States). Researchers at URJC and PSL Université Paris have demonstrated that the nano-formulation of the Ruthenium metal-drug is a result of the results of cell death that results in cellular cell results, after the application of the light, to open up future clinical trials of these therapeutic compounds.
As Santiago Gómez-Ruiz goes on: "In this sense, our work will activate the disease that may have less energy and clearer than UV light, such as UV-A, such as red or infrared light, would be excellent candidates for certain therapeutic interests today for direct applications ".